Marks & Clerk has long been recognised by clients and peers as one of the leading patent and trade mark attorney firms in the UK. We are also the largest with a network of 10 offices across the country.
Our patent and trade mark attorneys together with our associated firm of solicitors offer clients a comprehensive range of intellectual property services - covering patents, trade marks, designs and copyright. This includes obtaining protection worldwide, portfolio management, strategic advice, commercial advice, licensing, enforcement, due diligence and litigation.
In the UK in particular, our set-up of attorneys and solicitors is unique and enables clients to benefit from the full range of intellectual property services from a single access point.
Clients can also access our extensive international network and intellectual property connections. We work very closely with our colleagues and IP contacts around the world to provide an integrated international service.
The size and extent of our resources means we are able to offer expertise covering an incredibly diverse range of technologies and industry sectors. This differentiates us. We not only have the technical expertise but we also fully understand the commercial issues and needs of our diverse client base.
Marks & Clerk is consistently ranked a top tier firm in the UK for both patents and trade marks in the Managing Intellectual Property World IP Survey and in the Legal 500 and Chambers legal directories. We are described as an "outstanding" firm with a "very professional" and "impressive team".
In 2010, we achieved ISO 9001 certification, the internationally recognised quality management systems standard.
Marks & Clerk UK offices: Aberdeen, Birmingham, Cambridge, Cheltenham, Edinburgh, Glasgow, Leicester, London, Manchester, Oxford
Latest news
- Marks & Spencer’s use of AdWords is trade mark infringement
- Superfast Patents?
- Marks & Clerk’s latest Life Sciences Report unveils the changing landscape within the sector
- Indian Supreme Court invalidates anti-cancer drug patent
- Biological Deposits and Priority
LinkedIn
Twitter
RSS news feed





